GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » LENSAR Inc (NAS:LNSR) » Definitions » Altman Z2-Score

LENSAR (LENSAR) Altman Z2-Score : -2.72 (As of May. 22, 2024)


View and export this data going back to 2020. Start your Free Trial

What is LENSAR Altman Z2-Score?

Altman Z2-Score, also known as Z"-Score, is used to predict the likelihood that a non-manufacturing company (excluding property/financial company) will face bankruptcy within a two-year period.

Warning Sign:

LENSAR has a Altman Z2-Score of -2.72, indicating it is in Distress Zones. This implies bankrupcy possibility in the next two years.

The zones of discrimination were as such:

When Altman Z2-Score <= 1.1, it is in Distress Zones.
When Altman Z2-Score >= 2.6, it is in Safe Zones.
When Altman Z2-Score is between 1.1 and 2.6, it is in Grey Zones.

The historical rank and industry rank for LENSAR's Altman Z2-Score or its related term are showing as below:

LNSR' s Altman Z2-Score Range Over the Past 10 Years
Min: -2.82   Med: -1.6   Max: 7.17
Current: -2.72

During the past 5 years, LENSAR's highest Altman Z2-Score was 7.17. The lowest was -2.82. And the median was -1.60.


LENSAR Altman Z2-Score Historical Data

The historical data trend for LENSAR's Altman Z2-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

LENSAR Altman Z2-Score Chart

LENSAR Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23
Altman Z2-Score
- 6.11 2.75 -2.29 -2.38

LENSAR Quarterly Data
Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Altman Z2-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -2.82 -2.45 -1.60 -2.38 -2.72

Competitive Comparison of LENSAR's Altman Z2-Score

For the Medical Devices subindustry, LENSAR's Altman Z2-Score, along with its competitors' market caps and Altman Z2-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


LENSAR's Altman Z2-Score Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, LENSAR's Altman Z2-Score distribution charts can be found below:

* The bar in red indicates where LENSAR's Altman Z2-Score falls into.



LENSAR Altman Z2-Score Calculation

Altman Z-Score model is an accurate forecaster of failure up to two years prior to distress. It can be considered the assessment of the distress of industrial corporations.

Z2-Score, also known as Z"-Score is the Z-Score for non-manufacturing companies excluding property/financial companies.

LENSAR's Altman Z2-Score for today is calculated with this formula:

Z=6.56*X1+3.26*X2+6.72*X3+1.05*X4_2
=6.56*0.4837+3.26*-1.7245+6.72*-0.1855+1.05*0.9282
=-2.72

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency. GuruFocus does not calculate Altman Z2-Score when X4_2 value is 0.

Trailing Twelve Months (TTM) ended in Mar. 2024:
Total Assets was $66.13 Mil.
Total Current Assets was $42.44 Mil.
Total Current Liabilities was $10.45 Mil.
Retained Earnings was $-114.05 Mil.
Pre-Tax Income was -2.157 + -3.926 + 2.568 + -8.753 = $-12.27 Mil.
Interest Expense was 0 + 0 + 0 + 0 = $0.00 Mil.
Total Liabilities was $34.30 Mil.

* Note that for stock reported semi-annually or annually, GuruFocus uses latest annual data as the TTM data.

X1=Working Capital/Total Assets
=(Total Current Assets - Total Current Liabilities)/Total Assets
=(42.435 - 10.446)/66.134
=0.4837

X2=Retained Earnings/Total Assets
=-114.048/66.134
=-1.7245

X3=Earnings Before Interest and Taxes/Total Assets
=(Pre-Tax Income - Interest Expense)/Total Assets
=(-12.268 - 0)/66.134
=-0.1855

X4_2=Net Worth/Total Liabilities
=(Total Stockholders Equity - Preferred Stock)/Total Liabilities
=(31.835 - 0)/34.299
=0.9282

The zones of discrimination were as such:

Distress Zones - 1.1 < Grey Zones < 2.6 - Safe Zones

LENSAR has a Altman Z2-Score of -2.72 indicating it is in Distress Zones.


LENSAR  (NAS:LNSR) Altman Z2-Score Explanation

The original Z-Score model was based on publicly traded manufacturing companies while the Z2-Score, also known as Z"-score can be used for any type of company excluding property/financial companies. Both Z-Score and Z2-Score describes the financial health of a company, and its likelihood of financial distress.

X1: The Working Capital/Total Assets (WC/TA) ratio is a measure of the net liquid assets of the firm relative to the total capitalization. Working capital is defined as the difference between current assets and current liabilities. Ordinarily, a firm experiencing consistent operating losses will have shrinking current assets in relation to total assets. Altman found this one proved to be the most valuable liquidity ratio comparing with the current ratio and the quick ratio. This is however the least significant of the five factors.

X2: Retained Earnings/Total Assets: the RE/TA ratio measures the leverage of a firm. Retained earnings is the account which reports the total amount of reinvested earnings and/or losses of a firm over its entire life. Those firms with high RE, relative to TA, have financed their assets through retention of profits and have not utilized as much debt.

X3, Earnings Before Interest and Taxes/Total Assets (EBIT/TA): This ratio is a measure of the true productivity of the firm's assets, independent of any tax or leverage factors. Since a firm's ultimate existence is based on the earning power of its assets, this ratio appears to be particularly appropriate for studies dealing with corporate failure. This ratio continually outperforms other profitability measures, including cash flow.

X4_2, Net Worth (Total Stockholders Equity - Preferred Stock)/Total Liabilities (NW/TL): it compares a company’s stock net worth with its total liabilities and can be used to assess the extent of its reliance on debt.

Read more about Altman Z2-Score, the original research on Z-Score and the additional research on Z2-Score.


Be Aware

Altman Z2-Score does not apply to financial companies.


LENSAR Altman Z2-Score Related Terms

Thank you for viewing the detailed overview of LENSAR's Altman Z2-Score provided by GuruFocus.com. Please click on the following links to see related term pages.


LENSAR (LENSAR) Business Description

Traded in Other Exchanges
N/A
Address
2800 Discovery Drive, Orlando, FL, USA, 32826
LENSAR Inc is a commercial-stage medical device company focused on designing, developing and marketing a femtosecond laser system for the treatment of cataracts. The company Laser System incorporates a range of proprietary technologies designed to assist the surgeon in obtaining visual outcomes, efficiency and reproducibility by providing imaging, simplified procedure planning, efficient design and precision. Its product portfolio consists of the LENSAR Laser System with Streamline IV and IntelliAxis and its associated consumable components. The consumable portion of the system consists of a disposable patient interface device, or PID, kit and a procedure license. Each procedure on each system requires the use of a PID kit.
Executives
Gary M Winer director C/O LENSAR, INC., 2800 DISCOVERY DRIVE, ORLANDO FL 32826
Aimee S Weisner director ONE EDWARDS WAY, IRVINE CA 92614
Nr-gri Partners Gp, Llc 10 percent owner 867 BOYLSTON STREET, 5TH FLOOR, #1361, BOSTON MA 02116
Nr-gri Partners, Lp 10 percent owner 867 BOYLSTON STREET, 5TH FLOOR, #1361, BOSTON MA 02116
Todd B Hammer director, 10 percent owner NORTH RUN CAPITAL PARTNERS, 867 BOYLSTON ST., 5TH FLOOR, #1361, BOSTON MA 02116
Thomas B Ellis director, 10 percent owner 867 BOYLSTON STREET, 5TH FLOOR, #1361, BOSTON MA 02116
North Run Advisors, Llc 10 percent owner 62 WALNUT STREET, WELLESLEY MA 02481
North Run Capital, Lp 10 percent owner 867 BOYLSTON STREET, 5TH FLOOR, #1361, BOSTON MA 02116
Staab Thomas R Ii officer: Chief Financial Officer C/O INSPIRE PHARMACEUTICALS, INC., 4222 EMPEROR BLVD., SUITE 200, DURHAM NC 27703
Kendra Wong officer: Principal Accounting Officer C/O LENSAR, INC., 2800 DISCOVERY DRIVE, SUITE 100, ORLANDO FL 32826
Elizabeth G. O'farrell director 932 SOUTHWOOD BLVD., INCLINE VILLAGE NV 89451
Alan B. Connaughton officer: Chief Operating Officer C/O LENSAR, INC., 2800 DISCOVERY DRIVE, ORLANDO FL 32826
Nicholas T Curtis director, officer: Chief Executive Officer C/O STAAR SURGICAL CO, 1911 WALKER AVE, MONROVIA CA 91016
Pdl Biopharma, Inc. 10 percent owner 59 DAMONTE RANCH PARKWAY, SUITE B-375, RENO NV 89521
Lindstrom Richard L Md director 2811 WESTWOOD PL, WAYZATA MN 55391